Twenty-four of 58 adults (41%) and 29 of 56 children (52%) had a BICR-confirmed objective response during the 24-cycle treatment phase; in addition, two adults and one child had confirmed responses ...
The FDA granted fast track designation to PAS-004, a macrocyclic MEK inhibitor, for NF1-associated plexiform neurofibromas ...
Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.
Excluding NF1-specific cancers, the SMR in the study by Uusitalo et a 16 l was 2.25 overall, 2.01 for men, and 2.48 for women. The increased SMR in women is driven, in part, by the 5.2-fold SMR for ...
Of the more than 3,000 variants that have been identified in the NF1 gene, only a handful of specific variants can be correlated to certain NF1 symptoms. In this post, I’ll discuss the major known ...
Neurofibromatosis 1 (NF1) is a rare genetic disorder that affects the nervous system, causing tumours to form on nerves throughout the body. It is also known as Von Recklinghausen disease, named after ...
Panelists discuss key findings supporting the use of MEK inhibitors, such as selumetinib, in treating NF1-associated plexiform neurofibromas, emphasizing its impact on clinical decision-making, ...
NF1 microdeletion syndrome is a common dominant genomic disorder responsible for around 5% of type I neurofibromatosis cases. The majority of cases are caused by mutations arising within the NF1 gene.
This genetic condition causes tumors to form on nerves throughout the body, often showing up as skin changes. The right treatment and management approach can help address symptoms and potential ...
CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...
Cred: SpringWorks Therapeutics. Mirdametinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2. Gomekli is the first medication approved for both adult and pediatric patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results